Odyssey Therapeutics, Inc. (NASDAQ:ODTX) Receives Average Recommendation of “Moderate Buy” from Analysts

Odyssey Therapeutics, Inc. (NASDAQ:ODTX) has received a consensus rating of “Moderate Buy” from the six ratings firms that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $32.00.

A number of equities analysts have issued reports on ODTX shares. JPMorgan Chase & Co. started coverage on shares of Odyssey Therapeutics in a research report on Tuesday, June 2nd. They set an “overweight” rating and a $26.00 target price for the company. Wedbush began coverage on shares of Odyssey Therapeutics in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $30.00 target price for the company. Oppenheimer reissued an “outperform” rating and issued a $40.00 price objective on shares of Odyssey Therapeutics in a research report on Thursday, June 18th. Cantor Fitzgerald began coverage on shares of Odyssey Therapeutics in a research report on Tuesday, June 2nd. They issued an “overweight” rating for the company. Finally, Wall Street Zen lowered shares of Odyssey Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, June 20th.

Odyssey Therapeutics Price Performance

Shares of ODTX opened at $18.06 on Friday. Odyssey Therapeutics has a 12-month low of $15.35 and a 12-month high of $20.30.

Odyssey Therapeutics (NASDAQ:ODTX) last announced its earnings results on Wednesday, June 17th. The company reported $999.00 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.31) by $1,000.31.

Insiders Place Their Bets

In other news, Director Dimension Capital Ii, L.P. acquired 1,111,111 shares of the business’s stock in a transaction dated Friday, May 8th. The stock was acquired at an average price of $18.00 per share, with a total value of $19,999,998.00. Following the completion of the transaction, the director directly owned 3,333,516 shares in the company, valued at approximately $60,003,288. This represents a 50.00% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Nan (Ln) Li acquired 1,111,111 shares of the business’s stock in a transaction dated Monday, May 11th. The stock was purchased at an average cost of $18.00 per share, with a total value of $19,999,998.00. Following the transaction, the director owned 3,333,516 shares of the company’s stock, valued at approximately $60,003,288. The trade was a 50.00% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders have acquired 4,183,777 shares of company stock valued at $75,319,986.